Pelacarsen no better than placebo in patients with high lipoprotein(a), heart disease
Ionis and Novartis' pelacarsen failed to reduce major adverse CV events in patients with high lipoprotein(a) and heart disease, according to the Lp(a)HORIZON trial. The drug did not outperform placebo in reducing CV events, with similar rates in both groups. The trial included 8,322 patients, with a median follow-up of 4.7 years. Despite the setback, experts urge continued research into lipoprotein(a) treatments.
How this was made
The 30-second read
Why it matters
The primary endpoint was not met (HR = 1.02, p = 0.76), marking the first major setback for a Lp(a)‑lowering drug in late‑stage development.
Market read
First disclosure of a pivotal trial failure for a leading Lp(a) therapeutic; likely short‑term downside for Ionis and Novartis, with broader implications for the RNA‑based cardiovascular space.
What to watch
The trial still demonstrated a 77% Lp(a) reduction, which could support future indications or combination strategies.
Background
Pelacarsen, an antisense oligonucleotide targeting lipoprotein(a), was tested in the Lp(a)HORIZON trial involving >8,300 cardiovascular patients.
Ticker impact
Ionis (IONS) co‑developed pelacarsen, which failed to meet its primary endpoint in the Lp(a)HORIZON trial.
likely downward pressure as investors reassess the Lp(a) program.
First disclosure of a pivotal Phase 3 failure for a lead antisense program; market typically reacts negatively.
Novartis (NVS) partnered on pelacarsen, which did not reduce major adverse CV events versus placebo.
likely modest downside as investors weigh the setback against broader pipeline.
Trial failure is a fresh, material data point for a major biotech asset; impact may be less severe than for Ionis.
Market effects
Lipoprotein(a) therapeutic space may face heightened scrutiny, affecting other antisense and RNA‑based programs.
US biotech sector could see modest pullback as investors digest the result.
Limited to companies with Lp(a) pipelines; broader market impact minimal.
Counterpoint
Some investors may view the trial as a catalyst for a rebound if the market overreacts to a single negative study.
Key entities
- CompanyIonis Pharmaceuticals
Co‑developer of pelacarsen, ticker IONS.
- CompanyNovartis AG
Co‑developer of pelacarsen, ticker NVS.
- DrugPelacarsen
Antisense oligonucleotide targeting Lp(a).
